Effect of Interferon in the Treatment of COVID-19: A Clinical Trial Study
Student Research in Translational Medicine,
Vol. 7 (2025),
1 Esfand 2025
https://doi.org/10.22037/srtm.v7.39591
Abstract
Background and Aim: COVID-19 is a pandemic disease that causes high rate of mortality and morbidity around the world. Except conducting many studies during this period, there is no definite treatment for COVID-19. Interferon is one of the controversial drugs for the treatment of COVID-19. In this study we aimed to evaluate the effect of interferon in the treatment of COVID-19.
Methods: In this double blind randomized clinical trial, 30 patients were treated with beta interferon in addition to the medical regimen of COVID-19 (hydroxychloroquine 200 mg twice a day and Kaletra 400 mg) as intervention group and 30 patients were treated only with hydroxychloroquine 200 mg twice a day and Kaletra 400 mg as control group. Demographic, historical, clinical and outcome of patients were compared between the two groups.
Results: There were no statistically significant differences between age, sex, smoking, past medical history, clinical manifestations, laboratory data and CT scan manifestations of patients between the two groups (P-values > 0.05). Interferon had a positive effect on prolonged QT in ECG. Patients who received interferon had shorter ICU admission time, lower mortality rate, and higher discharge rate (P-values < 0.05).
Conclusion: Interferon is an effective treatment in patients who are admitted to hospital due to COVID-19.
- COVID-19, SARS-CoV-2 Infection, Coronavirus Disease 2019, Interferon
How to Cite
References
2. Farrugia G, Plutowski RW, editors. Innovation lessons from the COVID-19 pandemic. Mayo Clinic Proceedings; 2020: Elsevier.
3. Dong E, Ratcliff J, Goyea TD, Katz A, Lau R, Ng TK, et al. The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned. The Lancet Infectious Diseases. 2022.
4. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama. 2020;323(18):1824-36.
5. Tsang TK, Wu P, Lin Y, Lau EH, Leung GM, Cowling BJ. Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study. The Lancet Public Health. 2020;5(5):e289-e96.
6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. jama. 2020;323(13):1239-42.
7. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS central Science. 2020;6(5):672-83.
8. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The lancet. 2020;395(10236):1569-78.
9. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet. 2020;395(10229):1033-4.
10. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific journal of allergy and immunology. 2020;38(1):1-9.
11. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases. 2020;71(15):762-8.
12. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Treatment of SARS with human interferons. The Lancet. 2003;362(9380):293-4.
13. Morra ME, Van Thanh L, Kamel MG, Ghazy AA, Altibi AM, Dat LM, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta‐analysis. Reviews in medical virology. 2018;28(3):e1977.
14. Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral research. 2020;178:104791.
15. Al-Tawfiq JA, Memish ZA. What are our pharmacotherapeutic options for MERS-CoV? : Taylor & Francis; 2014. p. 235-8.
16. Hensley LE, Fritz EA, Jahrling PB, Karp C, Huggins JW, Geisbert TW. Interferon-β 1a and SARS coronavirus replication. Emerging infectious diseases. 2004;10(2):317.
17. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antiviral therapy. 2004;9(6):1003-11.
18. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS medicine. 2006;3(9):e343.
19. Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, Naghibi Irvani SS, Mokhtari M, Shabani M, et al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Scientific reports. 2021;11(1):1-11.
20. Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. International immunopharmacology. 2020;88:106903.
21. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation. 2020;130(5):2620-9.
22. Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G. Cytokine profile and disease severity in patients with COVID-19. Cytokine. 2021;137:155323.
23. Villalba MCM, Ramírez OV, Jiménez MM, Garcia AA, Alfonso JM, Baéz GG, et al. Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients. Clinical Immunology. 2020;220:108576.
24. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrobial agents and chemotherapy. 2020;64(9):e01061-20.
25. Seyfi S, Latifi K, Zavareh MSH, Ezoji K, Mohammadnia-Afrozi M. Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients. International Immunopharmacology. 2021;101:108241.
- Abstract Viewed: 198 times
- PDF Downloaded: 95 times
